Back HIV/AIDS HIV/AIDS Topics HIV Prevention

BHIVA 2015: HIV+ Men on Antiretroviral Treatment Have Undetectable Rectal Viral Load

A small study assessing the infectiousness of HIV-positive gay men taking antiretroviral therapy has found that all study participants had an undetectable viral load in the rectum, according to a presentation at the British HIV Association (BHIVA) conference last week in Brighton. Men who had rectal gonhorrea or chlamydia did not have detectable virus either, suggesting that concerns about sexually transmitted infections raising the risk of HIV transmission may be unfounded when people are taking effective HIV treatment.

alt

Read more:

CROI 2015: Daily PrEP Leads to Better Adherence and Protective Drug Levels in Women

HIV-negative African women assigned to take once-daily Truvada for HIV pre-exposure prophylaxis (PrEP) achieved better adherence than those assigned to take PrEP twice-weekly or before and after sex, according to findings from the HPTN 067 trial presented at the recent 2015 Conference on Retroviruses and Opportunistic Infections (CROI) in Seattle.

alt

Read more:

HIV Risk Behavior Remains Common Among People Who Inject Drugs in U.S.

An analysis from the CDC's National HIV Behavioral Surveillance system found that 11% of injection drug users in 20 U.S. cities were HIV-positive in 2012, according to a report in the March 20 Morbidity and Mortality Weekly Report. One-third of the interviewees reported sharing used injection equipment, putting them at risk for acquiring HIV and hepatitis B and C, while a majority reported sex without condoms.

alt

Read more:

Women in PrEP Trial Feared Having to Leave Study if They Reported Low Adherence

Post-study interviews and computer questionnaires conducted with former participants in the Fem-PrEP trial of pre-exposure prophylaxis (PrEP) that reported zero effectiveness show that the women concealed their low adherence because -- despite reassurances from researchers -- they feared they would be asked to leave the study, according to a report in the April 2015 Journal of Acquired Immune Deficiency Syndromes.

alt

Read more:

Some Providers Remain Reluctant to Prescribe HIV Pre-Exposure Prophylaxis

Despite a growing body of evidence showing that Truvada (tenofovir/emtricitabine) pre-exposure prophylaxis, or PrEP, is highly effective for HIV prevention, less than half of surveyed healthcare providers are likely to prescribe it for at-risk heterosexuals or people who inject drugs -- though the likelihood approaches 80% for gay men with HIV-positive partners -- according to a study published in the April edition of HIV Specialist, the magazine of the American Academy of HIV Medicine (AAHIVM).

alt

Read more: